On June 14th, research team from Shanghai University, Fourth Military Medical University and State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases published a groundbreaking research paper titled "CD147-K148me2-Driven Tumor Cell-Macrophage Crosstalk Provokes NSCLC Immunosuppression via the CCL5/CCR5 Axis" in the journal "ADVANCED SCIENCE" (impact factor: 15.1). 

Immunosuppression is a critical factor in the progression of non-small cell lung cancer (NSCLC). A key player in this process is the Cluster of Differentiation 147 (CD147), a pro-tumorigenic factor that contributes significantly to NSCLC's immunosuppressive environment.

This study has highlighted the importance of a specific post-translational modification: di-methylation of CD147 at lysine 148 (CD147-K148me2). This modification, catalyzed by the methyltransferase NSD2, is prevalent in NSCLC and correlates with poor survival outcomes, particularly in advanced stages. CD147-K148me2 enhances the interaction between CD147 and cyclophilin A (CyPA), activating p38-ZBTB32 signaling and increasing CCL5 transcription and secretion by cancer cells. This leads to the infiltration of M2-like tumor-associated macrophages (TAMs) via the CCL5/CCR5 axis, reinforcing the immunosuppressive tumor microenvironment. Blocking CD147-K148me2 with the antibody 12C8 disrupts this pathway, suggesting a promising strategy for targeting NSCLC through post-translational modification interventions.

In conjunction with the research study, CD147 mutant (eGFP-N1-CD147-K148R) is generated by using a site-directed mutagenesis kit from SBS Genetech. Since 2000, SBS Genetech has been at the forefront of providing solutions in life sciences. We offer safer, superior quality, and more cost-effective products to preeminent researchers in more than 60 countries, empowering them to make new discoveries in biology. Our products have been widely utilized in academic research, with results often published in leading academic journals like Science, Cell, Cancer Cell, and Cell Metabolism. We firmly believe that through continuous innovation and research, we will continually infuse new vitality and possibilities into the field of life sciences.